-
AI, Machine Learning & Computational Biology3 days agoWhat a cancer survivor sees that AI could miss in trial design
Parexel’s Stacy Hurt draws on her experience with chemotherapy and as a caregiver to spot patient burdens that AI-assisted protocol design can overlook.
-
Drug Discovery & Therapeutics1 week agoA cancer drug worked in the lab — but not how scientists thought
Researchers uncovered the unexpected mechanism behind a cancer drug candidate, highlighting a persistent problem in drug discovery.
-
Clinical Trials & Development2 weeks agoAlzheimer’s trials need patients. Why are so many screened out?
A new report argues that more flexible eligibility criteria could widen pharma’s clinical trial pool without sacrificing safety.
-
Drug Discovery & Therapeutics2 weeks agoA new startup takes aim at a suspected culprit in autoimmune disease
Ai3Bio recently emerged from stealth with preclinical programs aimed at what it believes could be a root cause of autoimmune conditions: diseased T cells.
-
Regulatory Intelligence & Drug Approvals3 weeks ago5 key facts about the FDA expedited IND pilot program
The program, part of Operation TrialBlazer, aims to speed early research and help the U.S. bring trials back from overseas.
-
Drug Discovery & Therapeutics1 month agoEpilepsy R&D is breaking out of its old playbook
Genetic medicines and more selective small molecules are finally pushing the field toward new mechanisms — and potentially disease-modifying treatments.
-
Global Biotechnology & Pharmaceutical Markets1 month agoA hidden tradeoff in Trump’s drug pricing deals
The government has announced “most-favored-nation” pricing agreements with 26 pharma companies. But the deals could stymie other plans to lower the country’s spending on prescription drugs.
-
Global Biotechnology & Pharmaceutical Markets1 month agoA hidden tradeoff in Trump’s MFN drug deals
The government has announced pricing agreements with 26 pharma companies. But the deals could stymie other plans to lower the country’s drug spend.
-
Clinical Trials & Development2 months agoWhere female participation in clinical trials has caught up — and where gaps remain
Getting more women into drug R&D remains critical for boosting health outcomes. But in some disease areas, pharma is still falling behind.
-
Regulatory Intelligence & Drug Approvals2 months ago3 KRAS drugs to watch as the field expands
Revolution’s pancreatic cancer approval marked a milestone in RAS-targeted treatment. Now, new treatments from Revolution, Astellas and Genentech could be the next to make a mark...
FDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis
Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure
100 Million-Cell AI-Ready Dataset with Single-Cell and Proteomic Data Created by Parse and Nomic
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
